References
- Sibbald B, Roland M. Understanding controlled trials: Why are randomised controlled trials important? BMJ316, 201 (1998).
- Simes RJ. Clinical trials and “real-world” medicine [editorial]. Med. J. Aust.177, 410–411 (2002).
- De Angelis C, Drazen JM, Frizelle FA et al. Clinical Trial Registration: a statement from the International Committee of Medical Journal Editors. Ann. Intern. Med.141, 477–478 (2004).
- Dahm M, González P, Porteiro N. Trials, tricks and transparency: how disclosure rules affect clinical knowledge. J. Health Econ.28, 1141–1153 (2009).
- Glasser SP, Salas M, Delzell E. Importance and challenges of studying marketed drugs: what is a Phase IV study? Common clinical research designs, registries, and self-reporting systems. J. Clin. Pharmacol.47, 1074–1086 (2007).
- Vlahakes GJ. The value of Phase 4 clinical testing. N. Engl. J. Med.354(4), 413–414 (2006).
- Simes RJ. Publication bias: the case for an international registry of clinical trials. J. Clin. Oncol.4, 1529–1541 (1986).
- Curfman GD, Morrissey S, Drazen JM. Expression of concern: Bombardier et al. “Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis.” N. Engl. J. Med.353, 2813–2814 (2005).
- Harris G, Koli E. Lucrative drug, danger signals and the FDA. The New York Times, 10 June (2005).
- Avorn J. Dangerous deception – hiding the evidence of adverse drug effects. N. Engl. J. Med.355(21), 2169–2171 (2006).
- Harris G. Heart surgery drug pulled from market. The New York Times, 6 November (2007).
- Berenson A. Cardiologists question delay of data on 2 drugs. The New York Times, 21 November (2007).
- Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. N. Engl. J. Med.358(3), 252–260 (2008).
- Krimsky S. Conflict of interest and cost-effectiveness analysis. JAMA282(15), 1474–1475 (1999).
- Sismondo S. Pharmaceutical company funding and its consequences: a qualitative systematic review. Contemp. Clin. Trials29, 109–113 (2008).
- Davidoff F, De Angelis CD, Drazen JM et al.Sponsorship, authorship and accountability. N. Engl. J. Med.345(11), 825–826 (2001).
- Chan A-W, Hróbjartsson A, Haahr MT, Gøtzsche PT, Altman DG. Empirical evidence for selective reporting of outcomes in randomized trials. JAMA291, 2457–2465 (2004).
- Milgrom P. Good news and bad news: representation theorems and applications. Bell J. Econ.12, 380–391 (1981).
- Azoulay P. Do pharmaceutical sales respond to scientific evidence? J. Econ. Manage. Strat.11(4), 551–594 (2002).
- De Angelis CD, Drazen JM, Frizelle FA et al. Is this clinical trial fully registered?: a statement from the International Committee of Medical Journal Editors. JAMA293, 2927–2929 (2005).
- Laine C, Horton R, De Angelis CD. Clinical trial registration: looking back and moving ahead. N. Engl. J. Med.356, 2734–2736 177(1), 57 (2007).
- Tse T, Williams RJ, Zarin DA. Reporting “basic results” in ClinicalTrials.gov. Chest136, 295–303 (2009).
- Wood AJJ. Progress and deficiencies in the registration of clinical trials. N. Engl. J. Med.360, 824–830 (2009).
- Zarin DH, Tse T, Ide NC. Trial registration at ClinicalTrials.gov between May and October 2005. N. Engl. J. Med.353(26), 2779–2787 (2005).
- Sekeres M, Gold JL, Chan A-W et al. Poor reporting of scientific leadership information in clinical trial registries. PLoS ONE3(2), E1610 (2008).
- Henry E. Strategic disclosure of research results: the cost of proving your honesty. Econ. J.119, 1036–1064 (2009).
- Tufts Center for the Study of Drug Development. FDA requested postmarketing studies in 73% of recent new drug approvals. Impact Report6(4) (2004).
- Folland S, Goodman AC, Stano M. The Economics of Health and Health Care. Pearson Prentice Hall, NJ, USA (2004).
- Drazen MJ, Morrissey S, Curfman GD. Open clinical trials. N. Engl. J. Med.357(17), 1756–1757 (2007).
Websites
- Committee on Clinical Trial Registries. Developing a national registry of pharmacologic and biologic clinical trials: workshop report. Institute of Medicine, National Academies Press, Washington, DC (2006). www.nap.edu/catalog/11561.html.
- Dickersin K. Reporting and other biases in studies of Neurontin for migraine, psychiatric/ bipolar disorders, nociceptive pain, and neuropathic pain. (2008). www.dida.library.ucsf.edu/tid/oxx18r10
- ClinicalTrials.gov. www.clinicaltrials.gov
- Research and Markets. Phase IV clinical trials: post-marketing study, management structure, strategy and benchmarks (2007). www.researchandmarkets.com/reports/368249